Zach Weinberg

Zach Weinberg
Nationality	American
Occupation	Entrepreneur, biotechnology executive
Known for	Co-founder and CEO of Curie.Bio

Zachary "Zach" Weinberg is an American entrepreneur and biotechnology executive who co-founded Curie.Bio, a biotechnology company focused on drug discovery across oncology, immunology, inflammation, and other therapeutic areas. Weinberg, described as a serial entrepreneur, has been involved in founding and building multiple ventures over the course of his career. In 2023, Curie.Bio attracted significant attention in the biotechnology industry after raising more than half a billion dollars to pursue a novel approach to how new drugs are discovered and developed. Weinberg has spoken publicly about the mission of Curie.Bio to serve as a "copilot" for promising new scientific ideas, seeking to support biotech founders and accelerate the translation of research into new medicines. His work sits at the intersection of entrepreneurship, venture capital, and the life sciences, and he has been recognized by major business publications for his contributions to the biotechnology startup ecosystem.

Career

Early Ventures and Serial Entrepreneurship

Prior to founding Curie.Bio, Zach Weinberg established himself as a serial entrepreneur with experience across multiple business ventures. While detailed accounts of his earliest companies are limited in publicly available sources, his career trajectory ultimately led him to the biotechnology and life sciences sector, where he found a particular focus on enabling drug discovery and supporting other founders in bringing new therapeutics to market.

Curie.Bio

Weinberg is best known as the co-founder and chief executive officer of Curie.Bio, a biotechnology company that has attracted considerable attention for both the scale of its fundraising and the distinctiveness of its business model. In February 2023, Fast Company reported that Curie.Bio had raised more than half a billion dollars, a figure that placed it among the most well-funded new biotechnology ventures of its era. The company's stated mission is to transform how new drugs are discovered by acting as a "copilot" for promising scientific ideas across a range of therapeutic areas, including oncology, immunology, and inflammation.

Weinberg has described the rationale behind Curie.Bio as rooted in his observation that biotech founders often face systemic barriers in translating early-stage scientific breakthroughs into viable drug development programs. The company's approach involves providing capital, operational infrastructure, and strategic support to enable scientists and entrepreneurs to focus on the scientific and clinical aspects of their work rather than the administrative and fundraising burdens that often consume early-stage biotech ventures.

In September 2023, Weinberg appeared alongside Alexis Borisy on The Long Run, a podcast and interview series published by the Timmerman Report, a publication focused on the biotechnology industry. In the interview, Weinberg and Borisy discussed their shared vision for "freeing the biotech founders" — a phrase that encapsulated their philosophy of reducing the friction faced by scientist-entrepreneurs and enabling them to pursue high-impact drug discovery programs with greater speed and fewer distractions. Borisy, a well-known figure in biotech venture creation, joined Weinberg in articulating the thesis that the traditional model of biotech company formation — in which founders must spend significant time and energy on fundraising, corporate formation, and operational logistics — could be improved through a more integrated platform model.

The therapeutic focus areas of Curie.Bio, as described by Weinberg in public statements, include oncology (the study and treatment of cancer), immunology (the study of the immune system and immune-related diseases), and inflammation (a broad category encompassing conditions driven by inflammatory processes). By targeting these areas, the company positioned itself within some of the most active and scientifically dynamic segments of the pharmaceutical industry.

Biotech Investment Landscape

Weinberg's work with Curie.Bio has placed him within broader conversations about the role of venture capital and early-stage investment in the biotechnology sector. In July 2025, Endpoints News reported on a growing debate among U.S. biotech investors regarding China's rise in drug development, with some investors perceiving a national security threat and others seeking to capitalize on collaborative opportunities. While Weinberg was not specifically quoted in the article, the broader investment dynamics discussed in such reporting provide context for the environment in which Curie.Bio operates.

In May 2025, Business Insider published its annual "Seed 100" list, highlighting the best early-stage investors of the year. The publication noted the particular difficulty of seed-stage investing, where investors "often write a check after hearing just the smallest kernel of an idea." This characterization reflects the type of early-stage, high-risk environment in which Weinberg and Curie.Bio have operated, backing nascent scientific ideas and attempting to guide them toward clinical and commercial viability.

Recognition

Weinberg's work with Curie.Bio has been the subject of coverage in several prominent business and industry publications. Fast Company profiled the company and its fundraising achievement in February 2023, highlighting the scale of the capital raised and the novelty of Weinberg's approach to drug discovery. The Timmerman Report, a respected publication within the biotechnology community, featured Weinberg as a guest on its Long Run podcast series in September 2023, providing a platform for him to discuss his entrepreneurial philosophy and vision for the future of biotech company creation.

These media appearances positioned Weinberg as a notable figure in the biotechnology startup ecosystem, particularly in discussions about how the industry can better support early-stage scientific innovation and reduce barriers for biotech founders.

Disambiguation

The name "Zach Weinberg" is shared by several individuals in public life. In addition to the biotechnology entrepreneur described in this article, there is a Zachary Weinberg who was hired as Head Volleyball Coach at the University of Evansville, as announced by the university's Director of Athletics. That Zach Weinberg announced a summer camp schedule for the Purple Aces volleyball program in April 2025 and hired Drew Davis as an assistant coach in March 2025.

Additionally, a Zach Weinberg has been identified as an optometrist who publicly advocated for Ohio Senate Bill 36, writing an opinion piece published by Cleveland.com in November 2025 arguing that certain laser and eyelid procedures are within the scope of optometric education and training.

These individuals are not the same person as the biotechnology executive profiled in this article.